Innovation Pharmaceuticals Inc (IPIX)

[georgejjl]

The topline results for the Phase 2 Brilacidin OM trial could be released this week.

The investigators at each of the 16 trial sites have already determined which subjects in the trial have had an incidence of grade 3 or 4 oral mucositis. The CRO that Innovation Pharmaceuticals contracted to oversee the trial knows which subjects used a Brilacidin solution and which patients used a placebo solution for their swish and spit treatment. Therefore it is readily apparent the percentage of each arm that experienced grade 3 or 4 oral mucositis.

That is also true regarding adverse side effects.

This information is readily available.

The secondary outcome measures can be released later.

https://clinicaltrials.gov/ct2/show/NCT02324335?term=NCT02324335&rank=1

Good luck and GOD bless,

George